Wealth Enhancement Advisory Services, LLC Larimar Therapeutics, Inc. Transaction History
Wealth Enhancement Advisory Services, LLC
- $55.6 Billion
- Q2 2025
A detailed history of Wealth Enhancement Advisory Services, LLC transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Wealth Enhancement Advisory Services, LLC holds 13,629 shares of LRMR stock, worth $45,111. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,629Holding current value
$45,111% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LRMR
# of Institutions
113Shares Held
64.6MCall Options Held
93.5KPut Options Held
68K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$70.3 Million1.16% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$20 Million0.27% of portfolio
-
Janus Henderson Group PLC London, X05.57MShares$18.4 Million0.01% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.78MShares$15.8 Million5.31% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$11.3 Million6.65% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $143M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...